Clinical trial
An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With…
NCT00051779 · Chugai Pharma USA, Industry · Completed
Key facts
| NCT number | NCT00051779 |
|---|---|
| Title | An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer |
| Official title | A 24-Week Blinded Study Conducted at Multiple Centers, Evaluating the Safety and Effectiveness of Various Doses of the Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) When Randomly Assigned to Patients With Breast Cancer That Has Metastasized to Bone |
| Lead sponsor | Chugai Pharma USA, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Breast Cancer, Metastasis |
| Intervention type | Drug |
| Interventions | CAL |
| First posted | Jan 17, 2003 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: